OR WAIT null SECS
November 14, 2018
Experts believe that the contract development and manufacturing organization market will reach $17.38 billion by 2022, with disruptive business models using Industrial Internet of Things (IIot) and single-use technologies proving more profitable and efficient in the long term.
October 01, 2018
The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.
September 28, 2018
Specialist biopharmaceutical company, Alvotech, has announced receipt of a manufacturing license from the Icelandic Medicines Agency, applying to its biopharmaceutical facility based in Reykjavik, Iceland.
While food, shelter, and clothing are the primal essentials for life, hope-as embodied by modern medicine-has now become part of that human expectation.
September 13, 2018
The collaboration will focus on developing manufacturing solutions for biosimilars.
July 19, 2018
In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.
July 01, 2018
Biosimilars and biobetters face developmental challenges to achieving commercialization.
June 15, 2018
Biosimilars and biobetters have their own unique manufacturing strategies and challenges.
May 29, 2018
The European Commission has approved Zessly (infliximab), a biosimilar to Johnson & Johnson’s blockbuster Remicade (infliximab).
This marks the third FDA approval for the company’s second biomanufacturing plant in Incheon, Korea.